We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Thermo Fisher Scientific Announces Launch of Lentivirus Production Solution Aimed to Produce High Titer Lentiviral Vectors

GIBCO CTS LV-MAX Lentiviral Production System

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Thermo Fisher Scientific Announces Launch of Lentivirus Production Solution Aimed to Produce High Titer Lentiviral Vectors"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GIBCO CTS LV-MAX Lentiviral Production System is a complete lentivirus production solution designed to produce high titer lentiviral vectors. This is the first optimized LV vector production system in suspension culture designed to meet USP <1043> standards. The system provides a smooth transition from discovery through clinical and commercial manufacturing. The LV-MAX lentiviral production system reduces the cost of viral production, simplifies researchers’ workflow, utilizes regulatory compliant reagents and provides a clear path toward commercialization.

With the launch of the CTS LV-MAX lentiviral production system, Thermo Fisher Scientific has enhanced its industry-leading cell and gene therapy portfolio, providing a complete solution for production of clinically relevant lentiviral vectors.

Features/Benefits:
• Cost effective: Reduces costs by more than 50 percent when compared to competitors.
• High titers: Greater than 1 x 108 TU/mL (unconcentrated).
• Suspension Cell Culture System: The cGMP-banked HEK293 cell line for LV production facilitates large scale production.
• Research Grade and CTS Options: Seamless transition from discovery to commercial production, with CTS products conforming to USP <1043> recommendations, with Drug Master File or Regulatory Support Files.

Advertisement